Answers are grounded in this paper and cite their sources.
Introduction: Pediatric patients with relapsed or refractory Burkitt's lymphoma (BL) present as a major challenge due to their poor outcomes despite use of high-intensity chemotherapy and anti-CD20 monoclonal antibody (mAb). CAR-T has shown efficacy in treating refractory or relapsed leukemia and Non-Hodgkin Lymphoma in adult patients. The aim of our study is to assess the safety and efficacy of CAR-T in the treatment of refractory or relapsed BL in pediatric patients. Methods: Patients with refractory/relapsed BL were enrolled to clinical trial (ChiCTR18000144) during January 2018-January 2019. The inclusion criteria were: 1) No complete remission (CR) after at least 5 courses of standard chemotherapy plus anti-CD20 mAb; or 2) No partial remission (PR) or showing progression after 2 courses of second-line chemotherapy; and 3) High expression of at least one B cells markers (CD19/CD20/CD22) examined by immunohistochemistry. The highest expressed marker was chosen for the first round CAR-T target. The therapeutic doses of CAR-T range from 1x10^6 to 3x10^6 per kilogram of body weight each course. The CAR-T cell numbers and cytokines were measured weekly. Tumor responses were evaluated at day 30 and day 60 post infusion and every two months thereafter. Results: Five refractory or relapsed BL patients, aged 6 to 10 years with a median age of 8 years, were enrolled, 4 males (80%) and 1 female (20%) according to St Jude's staging at the initial diagnosis: 3 cases (60%) in stage III, 2 cases (40%) in stage IV, 1 case of CNS invasion (20%), 1 case of bone marrow invasion (20%). They all failed initial intense chemotherapy and anti-CD20 mAb treatment (Table 1). They were then treated with 1 to 3 rounds of CAR-T (Table 2). Patients were monitored for CAR-T side effects: fever, gastro-intestine discomfort, rash, capillary leak syndrome, Immuno-pneumonia, tremor, hypotension, immunocytopenia, abnormal coagulation, liver dysfunction. One patient (20%) was diagnosed of cytokine-release syndrome (CRS) grading I and the other four grading III(80%). All subjects recovered fully after active symptomatic and supportive treatment including application of glucocorticoids in CRS grading III, but no patient required Tombuzumab. There were no death events (Table 2). Three subjects (60%) achieved CR by one round of CD19 CAR-T cell therapy, while two subjects (40%) achieved PR with first round of CD19 CAR-T treatment and achieved CR with subsequent CD22 or CD22 and CD20 CAR-T. The overall response rate (OR) was 100% with a median follow up 249 days, range 62-382 days, last follow up date January 30, 2019. (Table 3). Currently, all patients were in event-free survival. Conclusion: CD19/CD20/CD22-CAR-T therapy showed a robust efficacy in pediatric patients with refractory and relapsed BL and the toxicity profiles were moderate and could be well controlled.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: